NIR-Driven Water Splitting H2 Production Nanoplatform for H2-Mediated Cascade-Amplifying Synergetic Cancer Therapy
Source abstract
Abstract
As a newly emerging treatment strategy for many diseases, hydrogen therapy has attracted a lot of attention because of its excellent biosafety. However, the high diffusivity and low solubility of hydrogen make it difficult to accumulate in local lesions. Herein, we develop a H2 self-generation nanoplatform by in situ water splitting driven by near-infrared (NIR) laser. In this work, core–shell nanoparticles (CSNPs) of NaGdF4:Yb,Tm/g-C3N4/Cu3P (UCC) nanocomposites as core encapsulated with zeolitic imidazolate framework-8 (ZIF-8) modified with folic acid as shell are designed and synthesized. Due to the acid-responsive ZIF-8 shell, enhanced permeability and retention (EPR) effect, and folate receptor-mediated endocytosis, CSNPs are selectively captured by tumor cells. Upon 980 nm laser irradiation, CSNPs exhibit a high production capacity of H2 and active oxygen species (ROS), as well as an appropriate photothermal conversion temperature. Furthermore, rising temperature increases the Fenton reaction rate of Cu(I) with H2O2 and strengthens the curative effect of chemodynamic therapy (CDT). The excess glutathione (GSH) in tumor microenvironment (TME) can deplete positive holes produced in the valence band of g-C3N4 in the g-C3N4/Cu3P Z-scheme heterojunction. GSH also can reduce Cu(II) to Cu(I), ensuring a continuous Fenton reaction. Thus, a NIR-driven H2 production nanoplatform is constructed for H2-mediated cascade-amplifying multimodal synergetic therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Hydrogen's biological and therapeutic effects · Anesthesia and Neurotoxicity Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry and Pharmaceutical Sciences, Qingdao Agricultural University, Qingdao 266109, China
Department of Thyroid and Breast Surgery, Chengyang People’s Hospital, Qingdao 266109, China
Science and Information College, Qingdao Agricultural University, Qingdao 266109, China
Funding
National Natural Science Foundation of China
References (32)
Show source-provided references
1. 10.1021/ar500160510.1021/ar5001605 ↗
2. 10.1002/anie.20170899610.1002/anie.201708996 ↗
3. 10.1038/s41557-018-0141-510.1038/s41557-018-0141-5 ↗
4. 10.1038/nm157710.1038/nm1577 ↗
5. 10.1021/acsami.7b0534610.1021/acsami.7b05346 ↗
6. 10.1021/acsnano.9b0512410.1021/acsnano.9b05124 ↗
7. 10.1039/C9TB00338J10.1039/C9TB00338J ↗
8. 10.1016/j.apmt.2018.01.00810.1016/j.apmt.2018.01.008 ↗
9. 10.1016/j.cej.2019.12371010.1016/j.cej.2019.123710 ↗
10. 10.1016/j.cej.2019.12333710.1016/j.cej.2019.123337 ↗
11. 10.1016/j.msec.2019.11032410.1016/j.msec.2019.110324 ↗
12. 10.1021/acsami.9b1584810.1021/acsami.9b15848 ↗
13. 10.7150/thno.4071510.7150/thno.40715 ↗
14. 10.1021/jacs.9b1104610.1021/jacs.9b11046 ↗
15. 10.1038/s41467-018-06630-210.1038/s41467-018-06630-2 ↗
16. 10.1039/C9NH00021F10.1039/C9NH00021F ↗
17. 10.1002/smll.20190461910.1002/smll.201904619 ↗
18. 10.1021/acsami.9b0967110.1021/acsami.9b09671 ↗
19. 10.1002/adfm.20190646610.1002/adfm.201906466 ↗
20. 10.1039/C9SC01615E10.1039/C9SC01615E ↗
21. 10.1039/C7NR05499H10.1039/C7NR05499H ↗
22. 10.1016/j.cej.2020.12452410.1016/j.cej.2020.124524 ↗
23. 10.1021/acsami.9b0832910.1021/acsami.9b08329 ↗
24. 10.1016/j.cej.2019.12323610.1016/j.cej.2019.123236 ↗
25. 10.1016/j.apcatb.2018.09.01010.1016/j.apcatb.2018.09.010 ↗
26. 10.1016/j.jhazmat.2019.12081210.1016/j.jhazmat.2019.120812 ↗
27. 10.1016/j.apcatb.2014.01.04610.1016/j.apcatb.2014.01.046 ↗
28. 10.1016/j.apcatb.2018.03.03610.1016/j.apcatb.2018.03.036 ↗
29. 10.1016/j.apsusc.2019.01.01810.1016/j.apsusc.2019.01.018 ↗
30. 10.1016/j.jcis.2019.04.03510.1016/j.jcis.2019.04.035 ↗
31. 10.1021/acs.inorgchem.7b0160110.1021/acs.inorgchem.7b01601 ↗
32. 10.1002/adfm.20190467810.1002/adfm.201904678 ↗